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Background: The highly active antiretroviral therapy (HAART) has altered the course of HIV infection, transforming
it from a fatal illness to a chronic condition, reducing morbidity and mortality. However, this therapy has led to an
increased incidence of metabolic problems such as insulin resistance, dyslipidemia, lipodystrophy and impaired
glucose metabolism.
The objectives of this study are to determine the prevalence of insulin resistance (IR) in a cohort of human
immunodeficiency virus (HIV)-infected patients on highly active antiretroviral therapy (HAART) and to investigate
the potentially associated factors.
Methods: We conducted a cross-sectional study including 219 adult patients with HIV on HAART. IR was determined
through the homeostasis model assessment (HOMA-IR) mathematical model, using fasting plasma glucose (FPG) and
insulin. Bivariate and multivariate analyses were performed to assess the association between demographic information,
clinical characteristics and laboratory results, and IR.
Results: 75 (34.2 %) [95 % confidence interval (CI) 28.9–40.9] HIV-patients on HAART showed IR. 61 (81 %) of these
patients were on HAART for more than one year, which was mainly composed by non-protease inhibitors drugs (88 %).
Metabolic syndrome (MS) was found in 59 (26.9 %) subjects. In the multivariate analysis, the factors associated with IR
were age≥ 46 years (Prevalence ratio = 2.767, 95 % CI 1.325 to 5.780) and greater body mass index (BMI) (Prevalence
ratio = 1.148, 95 % CI 1.054 to 1.250).
Conclusions: The prevalence of IR was 34.2 %. Factors associated with IR were age and BMI. We did not find any
significant association between IR and protease inhibitors (PI), which may be explained by the small number of patients
using PI as part of their HAART regimen included in our study.
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World Health Organization and UNAIDS report about
39.5 million HIV-infected people worldwide and about 2
million people in Latin America. In 2009, around 70,000
people were estimated to be infected in Peru. The advent
of HAART has altered the course of HIV infection,
transforming it from a fatal illness to a chronic condition
and thereby reducing morbidity and mortality [1]. How-
ever, antiretroviral therapy has also led to an increased* Correspondence: christie.turin@upch.pe
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© 2015 Guillen et al.incidence of metabolic problems such as IR, dyslipidemia,
lipodystrophy and impaired glucose metabolism [2].
HAART comprises a combination of at least three ac-
tive antiretroviral drugs against the virus which belong
to different classes of drugs with different sites of action.
The preferred initial regimen is the combination of two
nucleoside reverse transcriptase inhibitors with a non-
nucleoside reverse transcriptase inhibitor or with a PI.
The adverse effects of these medications include meta-
bolic disorders. The antiretroviral drugs most frequently
associated with the development of lipodystrophy and IR
are the PIs such as lopinavir, ritonavir and nelfinavir [3].
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betes mellitus (T2DM) are part of a plurimetabolic syn-
drome associated with HAART, thus, the detection of
this syndrome should be systematic. Guidelines recom-
mend testing FPG at the time of HIV diagnosis, before
initiating HAART, and every 6–12 months during treat-
ment [4]. Also, performing an oral glucose tolerance test
when a patient presents with abnormal fasting glucose is
recommended [5]. This strategy allows the detection of
most cases of T2DM; however, it misses some cases of
IR. An early diagnosis of IR could allow for lifestyle
modification in order to prevent progression to T2DM.
The HOMA mathematical model is a clinical and epi-
demiological tool used to estimate IR based on plasma
levels of fasting glucose and insulin [6]. In order to in-
vestigate the prevalence of IR and the potentially impli-
cated factors, we conducted a cross-sectional study in a
cohort of Peruvian HIV-patients on HAART using the
HOMA-IR. Moreover, we described the prevalence of
MS according to the criteria proposed by The National




The study was approved by the Institutional Review
Board of the Universidad Peruana Cayetano Heredia and
of the Hospital Nacional Cayetano Heredia. All the pa-
tients gave written informed consent to participate. Au-
thors take complete responsibility for the integrity of the
data and the accuracy of the data analysis.
Study description
A cross-sectional study of adult patients with HIV infec-
tion on HAART was carried out between June and
October 2012 at the Institute of Tropical Medicine
“Alexander von Humboldt”, in the Hospital Nacional
Cayetano Heredia in Lima, Peru.
Patients recruited were adults over 18 years of age di-
agnosed with HIV infection on HAART. We excluded
patients with a known history of carbohydrate metabol-
ism disorders (IGT, T2DM), diseases that alter insulin
sensitivity (Cushing syndrome, Acromegaly, Polycystic
ovary syndrome), use of corticosteroids, and pregnancy.
We obtained clinical records that included the follow-
ing variables: age, gender, family history of diabetes in a
first degree relative, smoking, blood pressure, weight,
height, BMI, waist circumference, regimen and duration
of HAART.
We obtained a fasting serum sample to measure levels
of glucose, insulin, and lipids. Insulin level determination
was performed using the immunoradiometric assay
based on the separation of antibody-coated tube (INS-
Irma DIAsource-Belgium). This method has a detectionlimit, defined as the concentration resulting in two stand-
ard deviations above the average link of the zero calibrator,
1 uIU/mL. The coefficient of variation intra-assay and
inter-assay were 1.5 % and 6.5 % respectively.
Blood glucose was measured by the glucose oxidase
method. Hyperglycemia was considered as a fasting glu-
cose value ≥ 100 mg/dL. Total cholesterol, high-density
lipoprotein cholesterol (HDL-C), and triglycerides were
determined by enzymatic method. Low-density lipopro-
tein cholesterol (LDL-C) was calculated according to the
Friedewald formula.
The presence of IR was determined by the HOMA
mathematical model using the following formula: [Insu-
lin (μU/ml × glucose (mmol/L)/22.5]. We defined IR as a
HOMA-IR value ≥ 2.1. This cutoff point was determined
in a previous study conducted at the Hospital Nacional
Cayetano Heredia in subjects with normal glucose toler-
ance tests [8].
Statistical analyses
Continuous variables were summarized using means and
standard deviations, and comparisons between groups
with and without IR were made using the Student’s t-test.
Categorical variables were summarized by frequencies and
percentages, and their association with the outcome vari-
able (IR) was determined using Fisher’s exact test. Expos-
ure variables with a “p” value below 0.10 in the bivariate
evaluation were tested in multivariate models using “Gen-
eralized Linear Models” with the backward stepwise
method, removing variable with p values over 0.05. Preva-
lence ratios, with their corresponding confidence intervals,
were calculated as measures of excess risk.
The analysis was performed with the statistical pro-
gram Stata SE version 11 (College Station, TX).
Results
Participant’s characteristics
In this study, the response rate was 100 %. The demo-
graphic information, family and social history of 219
subjects are presented in Table 1. The mean age of the
study population was 38.4 ± 10.1 years. Most of the par-
ticipants were male (67.1 %), 23.3 % had a first-degree fam-
ily history of T2DM and 24.7 % patients were smokers.
Regarding the treatment, (76.3 %) subjects were on
HAART over a year and the most commonly used regimen
did not include a PI (90.9 %).
Clinical characteristics and laboratory results
The mean BMI was 24.5 ± 3.6. Most patients had a nor-
mal weight (55.3 %), 32.0 % overweight, 8.2 % obese and
4.6 % underweight. The mean abdominal circumference
in men and women was 88.8 ± 9.0 cm and 87.1 ±
10.3 cm, respectively (Table 2). Laboratory results are
shown in Table 3.
Table 1 Comparison of general characteristics of HIV-infected patients on HAART with and without insulin resistance (IR)
General characteristics (n = 219) Total (n = 219) No IR (n = 144) IR (n = 75) PR P
Male, n (%) 147 (67.1) 96 (66.7) 51 (68.0) 1.041 0.844
Age 0.007
≤ 35 years, n (%) 95 (43.4) 70 (48.6) 25 (33.3) 1.000 Reference
36-45 years, n (%) 74 (33.8) 50 (34.7) 24 (32.0) 1.232 0.398
≥ 46 years, n (%) 50 (22.8) 24 (16.7) 26 (34.7) 1.976 0.002
Hispanics, n (%) 190 (86.7) 124 (86.1) 66 (88.0) 1.119 0.709
Family history of T2DM, n (%) 51 (23.3) 34 (23.6) 17 (22.7) 0.965 0.877
Cigarrette smoker, n (%) 54 (24.7) 40 (27.8) 14 (18.7) 0.701 0.186
>1 year on HAART, n (%) 167 (76.3) 106 (73.6) 61 (81.3) 1.357 0.249
HAART regimen with PI, n (%) 20 (9.1) 11 (7.6) 9 (12.0) 1.357 0.235
Abbreviations: HAART highly active antiretroviral therapy; IR insulin resistance; PR prevalence ratio; PI protease inhibitor; T2DM type 2 diabetes mellitus
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The prevalence of IR was 34.2 % (95 % CI 28.9 – 40.9).
MS was found in 26.9 % subjects and was more preva-
lent in the IR group (44.0 % vs 18.1 %) (p < 0.001). The
most frequently components of MS were low HDL-C,
hypertriglyceridemia, and hyperglycemia (Table 4).
Hyperglycemia was found in 103 (47 %) subjects, 9
(4.1 %) of them had serum glucose >125 mg/dl. 8 (3.7 %)
patients had hypertension. The prevalence of hypertri-
glyceridemia and low HDL-C was 48.4 % and 57.5 % re-
spectively (Table 4).
Comparison between the groups with and without insulin
resistance
Subjects with IR were older, had higher BMI, and were
more likely to have hyperglycemia, central obesity and
diastolic hypertension. With regard to the lipid profile,
although the patients with IR had higher triglycerides
levels, no significant differences were found when the
variable was categorized as hypertriglyceridemia. ThereTable 2 Clinical characteristics of HIV-infected patients on HAART w
Clinical characteristics Total (n = 219)
SBP, mmHg 104.7 ± 11.9
DBP, mmHg 68.5 ± 8.2
Weight, Kg 64.7 ± 11.5
BMI, Kg/m2 24.5 ± 3.6
BMI categories
Underweight, n (%) 10 (4.6)
Normal weight, n (%) 121 (55.3)
Overweight, n (%) 70 (32.0)
Obesity, n (%) 18 (8.2)
Abdominal circumf. (cm) 88.3 ± 9.5
Male, cm 88.8 ± 9.0
Female, cm 87.1 ± 10.3
Abbreviations: BMI body mass index, DBP diastolic blood pressure, SBP systolic bloowere no differences in gender, family history of T2DM,
cigarette smoking, duration of HAART, using PI and
systolic blood pressure (SBP).
In multivariate analysis, the factors associated with IR
were age ≥46 years (PR = 2.767, 95 % CI 1.325 to 5.780)
and greater BMI (PR = 1.148, 95 % CI 1.054 to 1.250)
(Table 5).
Discussion
In our study, the prevalence of IR was 34 %, two times
higher than that of the non-HIV-infected population9.
The reported prevalence rates of IR among HIV-patients
on HAART are highly variable, ranging from 13 % to
45.7 % [9]. Because our study did not have a control
group of patients without HIV infection, the HOMA-
IR’s cutoff was 2.1, which was based on a previous study
conducted at the Hospital Nacional Cayetano Heredia in
subjects without HIV infection and with similar geo-
graphical and ethnic characteristics. This value corre-
sponds to the 75th percentile value determined by thatith and without insulin resistance (IR)
No IR (n = 144) IR (n = 75) P
103.6 ± 11.4 106.8 ± 12.6 0.060
67.5 ± 7.8 70.4 ± 8.6 0.013
63.0 ± 11.6 67.9 ± 10.7 0.003
23.8 ± 3.6 25.6 ± 3.5 0.001
0.001
9 (6.3) 1 (1.3) 0.535
91 (63.2) 30 (40.0) Reference
35 (24.3) 35 (46.7) 0.011
9 (6.3) 9 (12.0) <0.001
86.8 ± 9.8 91.1 ± 8.2 0.001
88.2 ± 9.2 90.1 ± 8.5 0.219
83.9 ± 10.3 93.3 ± 7.2 <0.001
d pressure, SD standard deviation
Table 3 Laboratory results of HIV-infected patients on HAART with and without insulin resistance (IR)
Laboratory results Total (n = 219) No IR (n = 144) IR (n = 75) P
Triglycerides, mg/dL 189.4 ± 147.8 172.5 ± 120.6 221.9 ± 186.1 0.019
LDL-C, mg/dL 114.5 ± 50.4 110.5 ± 51.9 122.3 ± 46.8 0.101
HDL-C, mg/dL 41.5 ± 14.1 42.1 ± 14.4 40.2 ± 13.5 0.336
FPG, mg/dL 100.9 ± 19.8 97.4 ± 11.8 107.6 ± 28.6 <0.001
HOMA index 2.6 ± 3.0 1.2 ± 0.5 5.3 ± 3.7 <0.001
Female 2.6 ± 2.9 1.2 ± 0.5 5.5 ± 3.6 <0.001
Male 2.5 ± 3.0 1.1 ± 0.5 5.2 ± 3.8 <0.001
Abbreviations: FPG fasting plasma glucose, HDL-C high-density lipoprotein cholesterol, HOMA homeostasis model assessment, LDL-C low-densitylipoprotein cholesterol
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and normal weight. It is higher than the cutoff point of a
study made with Peruvian Andean adults living at 4100
m above sea level (HOMA= 1.4) and lower than the
value found for Peruvian metropolitan population living
at sea level (HOMA= 3.56) [10].
Through bivariate analysis, we found the following
variables to be associated with IR: age, diastolic blood
pressure, weight, BMI, abdominal circumference and
FGP. All of these variables are components traditionally
associated with the development of IR in the general
population [11]. Our study did not find a significant as-
sociation between IR and the use of PIs, in contrast to
other reports which showed a clear association [12, 13],
this may be explained by the small number of patients
[20 (9 %)] using PI as part of their HAART regimen in-
cluded in our study. In addition, we found that 9 of the
20 patients on PI used atazanavir, which has not been
associated with IR in published studies [14]. On the
other hand, the prevalence of IR was not significantly
higher among patients who were more than one year on
HAART compared to those who were less time on treat-
ment, suggesting that IR occurs early. However, our
study does not allow us to assess if the IR worsens with
the course of the HIV infection. To evaluate this correl-
ation, it would be necessary to conduct a longitudinal
study. The long-term effects of antiretroviral drugs are
poorly understood. Jemsek JG et al. found that theTable 4 Comparison of metabolic syndrome and its components in
Metabolic syndrome’s components Total (n = 219) N
Metabolic Syndrome, n (%) 59 (26.9) 26
Central Obesity, n (%) 49 (22.4) 25
Hypertriglyceridemia, n (%) 106 (48.4) 66
Low HDL-C, n (%) 126 (57.5) 81
Hyperglycemia, n (%) 103 (47.0) 58
100−125 g/dL 94 (42.9) 57
> 125 g/dL 9 (4.1) 1
High Blood Pressure, n (%) 8 (3.7) 4
Abbreviations: HDL-C high-density lipoprotein cholesterol, IR insulin resistancealteration of insulin sensitivity in the early stages of anti-
retroviral therapy tends to normalize over time [15].
In the multivariate analysis, through a logistic regres-
sion model using the variables that were significant in
the bivariate analysis, we found that patients older than
46 years have almost three times more risk of IR com-
pared with younger subjects. Similarly, we found an in-
creased risk of IR with higher BMI; for each unit
increase in BMI, the risk of IR increased by 15 %. The
prevalence of MS in our series was 27 %, similar to the
prevalence reported in American and Latin American
series in patients with HIV infection [16, 17], and
higher than the prevalence found in the Peruvian adult
population without HIV infection (22 %) [18]. With re-
gard to the components of MS, in our study, similar to
other studies of MS in HIV patients, dyslipidemia and
hyperglycemia predominant followed by obesity and
hypertension. Also, a high percentage of patients with
MS had normal weight, which differs from previous re-
ports about MS in the general population, where ab-
dominal obesity and hypertension are the principal
components [19].
We found an alarmingly high prevalence of hypergly-
cemia (47 %), higher than that reported in other studies
of HIV patients on HAART (38 %) [20], these results
suggest that HIV treatment is an important factor in the
development of IR and other metabolic disorders such
as IGT and T2DM. Unfortunately, our study did notHIV-infected patients on HAART with and without IR
o IR (n = 144) IR (n = 75) PR P
(18.1) 33 (44.0) 2.131 <0.001
(17.4) 24 (32.0) 1.633 0.007
(45.8) 40 (53.3) 1.218 0.297
(56.3) 45 (60.0) 1.107 0.600
(40.3) 45 (60.6) 1.689 0.008
(39.6) 37 (49.3) 1.86 0.038
(0.7) 8 (10.7) 2.75 0.004
(2.8) 4 (5.3) 1.486 0.258
Table 5 Multivariate logistic regression analysis for IR in HIV-
infected patients on HAART
Factor PR P 95 % CI
Age (years) 0.014
≤ 35 1.000 Reference
36-45 1.070 0.848 0.533 2.150
≥ 46 2.767 0.007 1.325 5.780
BMI 1.148 0.002 1.054 1.250
Abbreviations: BMI body mass index, CI confidence interval, PR prevalence ratio
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cases of T2DM undiagnosed.
The prevalence of hypertension was 3.7 %, lower than
that found in a previous study (16 %) [21]. This low
prevalence may be due to the lower age of the enrolled
patients.
The study’s limitations were the lack of a control
group of HIV-uninfected subjects to define a more pre-
cise HOMA-IR’s cutoff point and the clinical evaluation
of lipodystrophy. In addition, variables such as CD4
count and viral load were omitted. These variables have
been considered factors associated with IR in this spe-
cific population. Squillace N et al. found a significant as-
sociation between a high CD4 count and IR [22].
However, El-Sadr WM et al. has shown an inverse rela-
tionship between CD4 count and IR [23]. These incon-
sistent associations, on regard the CD4 count, might
reflect underlying immunological mechanisms that could
affect the insulin sensitivity. Therefore, those two vari-
ables must be included in future studies as possible
underlying factors. Finally an oral glucose tolerance test
was not performed to diagnose T2DM.
Conclusion
In conclusion, this study shows a significant percentage
of HIV-infected patients on HAART present IR. Factors
associated with IR were age and BMI. Since these pa-
tients have a high frequency of dyslipidemia and tobacco
consumption, the detection of IR and its risk factors will
allow for the assessment of each patient’s metabolic risk
and will also promote addressing modifiable risk factors
to prevent the development of T2DM and cardiovascular
disease.
We did not find any significant association between IR
and protease inhibitors, which may be explained by the
small number of patients using PI as part of their
HAART regimen included in our study.
Based on our results, we suggest following current
guidelines for the use of antiretroviral therapy in HIV
patients, which recommend performing laboratory tests,
such as fasting glucose or OGTT, during follow-up. The
use of HOMA-IR in these patients will require furtherlongitudinal studies in order to demonstrate its usefulness
in early predicting diabetes or IGT in this population.
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